Source comparison
Sermorelin vs HGH Therapy — Which Protocol Fits Your Goals?
A 2019 study published in Growth Hormone & IGF Research found that sermorelin therapy increased endogenous growth hormone secretion by 30–50% in adults with age-related GH deficiency. Without suppressing the pituitary's natural pulsatile release pattern. Synth
This comparison does not assign a generated winner or score.
- A 2019 study published in Growth Hormone & IGF Research found that sermorelin therapy increased endogenous growth hormone secretion by 30–50% in adults with age-related GH deficiency. Without suppressing the pituitary's natural pulsatile release pattern. Synthetic HGH, by contrast, delivers a fixed dose of exogenous somatropin that overrides your body's feedback loops entirely. The difference isn't subtle.
- We've worked with researchers across multiple disciplines who test peptide compounds in controlled settings. The gap between doing sermorelin vs HGH therapy correctly comes down to understanding what each protocol does at the receptor level. And what it doesn't do.
- What's the difference between sermorelin and HGH therapy?
- Sermorelin is a growth hormone-releasing hormone (GHRH) analog that stimulates your anterior pituitary to produce more endogenous growth hormone. HGH therapy delivers synthetic recombinant human growth hormone (somatropin) directly into circulation, bypassing pituitary regulation. Sermorelin preserves natural pulsatile GH release; synthetic HGH creates sustained supraphysiological levels. The former works through upstream signaling; the latter replaces the hormone itself.
- Here's what that actually means in practice. Sermorelin doesn't give you growth hormone. It tells your pituitary to make more. If your pituitary is damaged, non-responsive, or fully suppressed, sermorelin won't generate the effect you're looking for. Synthetic HGH doesn't care about your pituitary's condition because it's delivering the end product directly. This piece covers the mechanisms that distinguish sermorelin vs HGH therapy, the clinical scenarios where one outperforms the other, and what the research shows about long-term safety and cost differences.